Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children

Open access
Trautmann, Agnes, Schnaidt, Sven, Lipska-Ziętkiewicz, Beata S., Bodria, Monica, Ozaltin, Fatih, Emma, Francesco, Anarat, Ali, Melk, Anette, Azocar, Marta, Oh, Jun, Saeed, Bassam, Gheisari, Alaleh, Caliskan, Salim, Gellermann, Jutta, Higuita, Lina Maria Serna, Jankauskiene, Augustina, Drozdz, Dorota, Mir, Sevgi, Balat, Ayse, Szczepanska, Maria, Paripovic, Dusan, Zurowska, Alexandra, Bogdanovic, Radovan, Yilmaz, Alev, Ranchin, Bruno, Baskin, Esra, Erdogan, Ozlem, Remuzzi, Giuseppe, Firszt-Adamczyk, Agnieszka, Kuzma-Mroczkowska, Elzbieta, Litwin, Mieczyslaw, Murer, Luisa, Tkaczyk, Marcin, Jardim, Helena, Wasilewska, Anna, Printza, Nikoleta, Fidan, Kibriya, Simkova, Eva, Borzecka, Halina, Staude, Hagen, Hees, Katharina, Schaefer, Franz, for the PodoNet Consortium · 2017 · Journal of the American Society of Nephrology

Abstract

We investigated the value of genetic, histopathologic, and early treatment response information in prognosing long-term renal outcome in children with primary steroid-resistant nephrotic syndrome. From the PodoNet Registry, we obtained longitudinal clinical information for 1354 patients (disease onset at >3 months and <20 years of age): 612 had documented responsiveness to intensified immunosuppression (IIS), 1155 had kidney biopsy results, and 212 had an established genetic diagnosis. We assessed risk factors for ESRD using multivariate Cox regression models. Complete and partial remission of proteinuria within 12 months of disease onset occurred in 24.5% and 16.5% of children, respectively, with the highest remission rates achieved with calcineurin inhibitor–based protocols. Ten-year ESRD-free survival rates were 43%, 94%, and 72% in children with IIS resistance, complete remission, and partial remission, respectively; 27% in children with a genetic diagnosis; and 79% and 52% in children with histopathologic findings of minimal change glomerulopathy and FSGS, respectively. Five-year ESRD-free survival rate was 21% for diffuse mesangial sclerosis. IIS responsiveness, presence of a genetic diagnosis, and FSGS or diffuse mesangial sclerosis on initial biopsy as well as age, serum albumin concentration, and CKD stage at onset affected ESRD risk. Our findings suggest that responsiveness to initial IIS and detection of a hereditary podocytopathy are prognostic indicators of favorable and poor long-term outcome, respectively, in children with steroid-resistant nephrotic syndrome. Children with multidrug-resistant sporadic disease show better renal survival than those with genetic disease. Furthermore, histopathologic findings may retain prognostic relevance when a genetic diagnosis is established.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2016101121

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 227

Metadata

Authors
Trautmann, A., Schnaidt, S., Lipska-Ziętkiewicz, B. S., Bodria, M., Ozaltin, F., Emma, F., Anarat, A., Melk, A., Azocar, M., Oh, J., Saeed, B., Gheisari, A., Caliskan, S., Gellermann, J., Higuita, L. M. S., Jankauskiene, A., Drozdz, D., Mir, S., Balat, A., Szczepanska, M., Paripovic, D., Zurowska, A., Bogdanovic, R., Yilmaz, A., Ranchin, B., Baskin, E., Erdogan, O., Remuzzi, G., Firszt-Adamczyk, A., Kuzma-Mroczkowska, E., Litwin, M., Murer, L., Tkaczyk, M., Jardim, H., Wasilewska, A., Printza, N., Fidan, K., Simkova, E., Borzecka, H., Staude, H., Hees, K., Schaefer, F., & for the PodoNet Consortium
Venue
Journal of the American Society of Nephrology
Published
2017-05-31
Volume
28
Issue
10
Pages
3055-3065
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2618084763
Cited by
227
References
2
FWCI
12.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.